Clinical Trials Using Defactinib

Clinical trials are research studies that involve people. The clinical trials on this list are studying Defactinib. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-3 of 3
  • Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

    This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.
    Location: 1172 locations

  • Defactinib, Pembrolizumab, and Gemcitabine Hydrochloride in Treating Patients with Advanced Pancreatic Cancer or Solid Tumors

    This phase I trial studies the side effects and best dose of defactinib when given together with pembrolizumab and gemcitabine hydrochloride in treating patients with pancreatic cancer or a solid tumor that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Defactinib may stop the growth of tumor cells by blocking an enzyme needed for cell growth. Monoclonal antibodies, such as pembrolizumab, may find tumor cells and help kill them. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving defactinib, pembrolizumab, and gemcitabine hydrochloride together may work better in treating patients with pancreatic cancer.
    Location: 2 locations

  • Window of Opportunity Study of VS-6063 (Defactinib) in Participants With Surgical Resectable Malignant Pleural Mesothelioma.

    This is an open label neoadjuvant (treatment with VS-6063 prior to mesothelioma surgery) study in subjects with malignant pleural mesothelioma who are eligible for surgery. Subjects will receive VS-6063 (defactinib) 400 mg twice daily for 12, 21, or 35 days. Pre- and post-treatment biopsies and blood samples will be collected. The purpose of this study is to assess biomarker responses from tumor tissue. The safety, pharmacokinetics, and tumor response rate to VS-6063 (defactinib) will be also be assessed.
    Location: See Clinical